MediWound announces marketing approval of NexoBrid in Australia

MediWound (MDWD) announced that Australia’s Therapeutic Goods Administration, TGA, has granted marketing authorization for NexoBrid, the Company’s enzymatic therapy for the removal of eschar in both adult and pediatric patients with deep partial- and full-thickness thermal burns. “The TGA approval of NexoBrid marks another important step in expanding access to innovative, non-surgical burn care,” said Ofer Gonen, Chief Executive Officer of MediWound. “Together with our partner Balance Medical, we will ensure that burn centers across Australia have access to this therapy. Importantly, this milestone also opens the door to the broader Asia-Pacific region, where we see growing demand for advanced wound and burn treatments.”